5w6m
From Proteopedia
(Difference between revisions)
m (Protected "5w6m" [edit=sysop:move=sysop]) |
|||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Crystal structure of the human histidyl-tRNA synthetase mutant D175E== | |
- | + | <StructureSection load='5w6m' size='340' side='right' caption='[[5w6m]], [[Resolution|resolution]] 3.70Å' scene=''> | |
- | + | == Structural highlights == | |
- | + | <table><tr><td colspan='2'>[[5w6m]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5W6M OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5W6M FirstGlance]. <br> | |
- | + | </td></tr><tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr> | |
- | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5w6m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5w6m OCA], [http://pdbe.org/5w6m PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5w6m RCSB], [http://www.ebi.ac.uk/pdbsum/5w6m PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5w6m ProSAT]</span></td></tr> |
+ | </table> | ||
+ | == Disease == | ||
+ | [[http://www.uniprot.org/uniprot/SYHC_HUMAN SYHC_HUMAN]] Defects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:[http://omim.org/entry/614504 614504]]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.<ref>PMID:22279524</ref> Note=HARS mutations may be involved in peripheral neuropathy, a disease mainly characterized by distal motor and sensory dysfunction. Inherited peripheral neuropathies are clinically and genetically heterogeneous with variable age of onset and reduced penetrance associated with specific loci. HARS mutations may directly predispose patients to peripheral neuropathy or may modify a peripheral neuropathy phenotype by contributing to the genetic and environmental load in a given patient (PubMed:22930593). | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Histidine--tRNA ligase]] | ||
[[Category: Blocquel, D]] | [[Category: Blocquel, D]] | ||
- | [[Category: Yang, X | + | [[Category: Yang, X L]] |
+ | [[Category: Cmt mutant]] | ||
+ | [[Category: Ligase]] | ||
+ | [[Category: Trna-synthetase]] |
Revision as of 05:40, 20 June 2018
Crystal structure of the human histidyl-tRNA synthetase mutant D175E
|